TruthArchive.ai - Related Video Feed

Gene injections, also known as vaccines, aim to stimulate adaptive immunity and neutralizing antibodies to eliminate the virus. However, the Pfizer and Moderna vaccines have shown negative efficacy, with vaccinated individuals getting infected and reinfected. This leads to the emergence of more infectious variants. Continuing the current vaccine rollout will prolong the pandemic, as new variants will keep emerging. Vaccinating during a pandemic with high infectious pressure is a catastrophic mistake. These vaccines cannot and will not work.

Dr. Hotez explains that while vaccines are often described as miraculous, the development was not a four-month process but a seventeen-year effort dating back to the post-SARS period. After SARS emerged in 2003, researchers identified the spike protein as the virus’s soft underbelly and began experimental vaccine development. When the COVID-19 sequence was released in January, the coronavirus community quickly concluded that a vaccine could be made, and attention turned to which technology would be fastest and most enduring. All vaccines discussed (AstraZeneca, Pfizer, Moderna, J&J, and the one being scaled in India) target the spike protein. He emphasizes that this was a deliberate long-term program, not a rushed push. Nicole notes the broader context of vaccine safety, particularly on a day when a vaccine-skeptical witness testified before the Senate Homeland Security Committee. Dr. Hotez clarifies that the virus behind the current pandemic comes from a family of coronaviruses scientists have studied for a long time, and that once specifics emerged, researchers could finalize the vaccine approach. He reiterates the importance of reassurance about safety in light of public skepticism. Dr. Hotez highlights the role of the NIH and the National Institute of Allergy and Infectious Diseases, led by Tony Fauci, and Francis Collins at NIH, in launching a major coronavirus program beginning in 2003. This funding enabled the development of some of the first prototype vaccines, illustrating a deliberate US government and NIH investment to advance vaccine research. He notes the ongoing need to assess rollout and production robustness, as this technology is brand new, and additional vaccines will be necessary to vaccinate populations. Looking ahead, the conversation acknowledges that the United States will require four or five different vaccines to achieve broad vaccination coverage, rather than relying solely on the two mRNA vaccines. The UK has begun vaccinations, marking an initial step, with plans to scale in the United States in the coming days. The discussion underscores a long road ahead to ensure scalable production, distribution, and multiple vaccine options to meet demand.

We were all hopeful when we heard the vaccine was 95% effective, thinking it was our way out. But maybe we were too optimistic and not cautious enough. We didn't consider the possibility of the vaccine wearing off or being less effective against future variants.

Vaccines are seen as magical but expectations should be tempered. Pfizer's vaccine is 95% effective, but efficacy drops over time. Boosters may be needed annually. Moderna is working on a combined flu and COVID vaccine. The future is uncertain, but we must adapt.

Vaccine development typically takes 10 to 25 years, with the fastest recorded time in the U.S. being around 3 to 4 years. This timeline reflects the necessary clinical testing to ensure safety and efficacy. The development cycle for COVID-19 vaccines aligns closely with previous vaccine timelines, showing only modest variations. It's important for people to understand this process to alleviate concerns about the COVID-19 vaccines.

Vaccines are often seen as a solution, but expectations may be too high. Initially, a vaccine was touted as providing lifetime immunity, but that may not be realistic. Over time, efficacy rates have dropped significantly, with reports showing effectiveness decreasing from 95% to as low as 33%. Immunity may last only a few months, requiring regular boosters, similar to the flu vaccine. The focus may shift to annual shots rather than a one-time solution. As companies work on combining COVID and flu vaccines, the reality is that COVID is likely here to stay, and ongoing adjustments will be necessary.

Vaccination is crucial for protecting oneself and others, and for society to return to normal. Vaccinated individuals are less likely to transmit the virus or get sick. Getting vaccinated and receiving booster shots can save lives and prevent the spread of infection. The goal is to become a dead end for the virus, stopping its transmission. Vaccinated people do not get infected and cannot be used as hosts to spread the virus. However, the initial emergency use authorization did not have sufficient data on the vaccine's effect on transmission. The speed of scientific progress necessitated quick action.

mRNA vaccines code for a small part of viral proteins, usually a single antigen. A single mutation can make the vaccine ineffective. This drives antigenic shift, where the vaccine encourages new mutations, prolonging pandemics as the virus mutates to escape the vaccine's protection. Millions caught the Omicron variant despite vaccination because a single mutation can render mRNA vaccines ineffective. The same risk applies to the flu.

The speaker acknowledges that the vaccine did not completely stop the spread or infection, but clarifies that initially it did for the Wuhan strain and the alpha strain. Early data and literature published in the New England Journal showed that those who were vaccinated and didn't get infected were not transmitting the virus to others. The vaccine had a high efficacy of up to 96% early on and this efficacy did not change over time.

The speaker discusses the arrival of the vaccine and its effectiveness in preventing transmission. They mention that the vaccine was a pleasant surprise for the medical community, as it initially seemed to protect against severe forms of the virus and transmission. However, further observations revealed that the vaccine's duration of protection was relatively short, especially in older individuals, and its ability to limit transmission was limited. The speaker acknowledges that they and the scientific council may have made mistakes in their understanding of the vaccine's effects. They also address concerns about the vaccine's safety and emphasize the importance of ongoing monitoring. Overall, the vaccine provided some protection against severe forms of the virus but did not meet expectations in terms of transmission prevention.

The vaccine is effective against infection and transmission, but immunity decreases after 6 months. A booster or third dose is needed to restore immunity. Translation: The vaccine works well against getting sick and spreading the virus, but protection weakens after 6 months. To boost immunity, a third dose is necessary.

The situation has been horrific, leading to a shift in research and development budgets. Current vaccines primarily focus on improving individual health but only slightly reduce transmission. There is a need for a new approach to vaccine development that effectively blocks transmission.

Developing an effective and safe vaccine takes around 10 to 25 years, with the current record in the US being 3 to 4 years. The timeline for COVID-19 vaccines follows a similar progression as other vaccines. There are some minor differences, but overall, the development cycle is similar. It's important for people to understand this if they have concerns about taking COVID-19 vaccines.

During the pandemic, the development of vaccines surprised many due to its speed. The government's Operation Warp Speed invested $11 billion to accelerate the process, taking the risk out of it for pharmaceutical companies. Within 11 months, large phase three trials were conducted for Pfizer and Moderna's mRNA vaccines. Comparatively, the development of the polio vaccine took several years. Despite the rapid development and effectiveness of the COVID-19 vaccines, there was a significant portion of the population, around 30%, who chose not to get vaccinated. This resistance was unexpected and only strengthened the anti-vaccine movement. The speaker expresses frustration at the missed opportunities to prevent hospitalizations and deaths, particularly among unvaccinated children.

Vaccines are seen as magical, but expectations may need to be lowered. Pfizer's vaccine is 95% effective, but efficacy rates can fluctuate. Protection may only last a year, requiring annual shots. Moderna is working on a combined flu and COVID vaccine. The future is uncertain, but there is hope for improvement in the next 5 years.

We are generating real-time data on mRNA vaccines, which have been in development for years due to side effects. Pfizer and Moderna used the pandemic to accelerate their development. The collaboration with BioNTech on flu led to the quick rollout of the mRNA vaccine. Clinical trials skipped phases, causing uncertainty. Concerns arise about vaccine distribution and the need for booster shots. Politics play a role in decision-making.

Speaker 0 and Speaker 1 discuss the COVID-19 vaccine episode, challenging why the vaccine was pursued as a public health solution and exploring deeper incentives behind the program. - A knowledgeable figure at the stand answered a burning question: did they know the vaccine wouldn’t be effective from the start and could be dangerous? The answer given was that it was “a test of a technology.” The exchange suggests the broader aim was testing an entire program of control previewed in Event 2019. - They ask whether inoculation was necessary on billions, noting it could have been tested on a much smaller population. If shots had been basically empty or inert, the data could have been spun to claim success and end the pandemic, preventing injuries from appearing. The absence of that approach remains a mystery. - The speakers point to high pre-vaccine seroprevalence in 2020, including studies from South Dakota showing 50-60% seroprevalence before vaccine release, implying that a saline shot or no shot could have achieved “indomicity” (immunity) without a vaccine. - They discuss why people might fear vaccines and interpret the broader impact: the public is waking up to something terrible having occurred, as it revealed readiness to lie, potential data quality concerns, and risk to pregnant women and healthy children who might get little justification for risk. - The disease’s lethality is framed as greatest among the very old or very sick; for others, it was less deadly, with natural evolution potentially reducing vulnerability over time. - The mRNA platform was touted as a means to outrun mutations, but the timeline to release was still insufficient to stay ahead of natural change. They note accelerated development was the fastest vaccine in history, from detection to inoculation, reducing the timeline by about a year or two, yet not fast enough. - Political and logistical factors delayed release; there is mention that it would not have appeared under Trump and that Eric Topol argued to delay the rollout. Fauci reportedly sent Moderna back to trials due to insufficient racial diversity in participants. - The discussion questions whether the vaccine qualifies as a normal consumer product, given ongoing subsidies, mandates, indemnifications, wartime-like supports, and propaganda. They wonder if there has been an ongoing two-century revolt by industry against public scrutiny, with public interest repeatedly leading to pushback and rebranding. - A central theme is the sophistication of pharma: the “game of pharma” involves owning an IP-based health claim, crafting supportive research, convincing it is safe and effective, achieving standard-of-care status, securing mandates and government funding, and leveraging ongoing propaganda. They describe pharma as a long-running arms race with deep institutional knowledge, implying that it is far more capable of shaping reality than the public realizes.

Developing a safe and effective vaccine typically takes 10 to 25 years, with the fastest in the US being around 3 to 4 years. The timeline for COVID-19 vaccines is similar to other vaccines, with some minor differences. This should reassure those hesitant about getting vaccinated.

The Pfizer COVID vaccine was not tested for its ability to stop the transmission of the virus before it entered the market. The speaker acknowledges that they had to work quickly to understand the situation and move at the speed of science.

I've been involved in over 50 vaccines, including mRNA vaccines. mRNA is like DNA, giving cells instructions to make proteins. This technology was originally for gene therapy, now used for vaccines. It's a new, experimental technology never used in humans before COVID. Animal studies were skipped for COVID vaccines, a novel approach.

Vaccination is crucial for protecting oneself and others, and for society to return to normal. Vaccinated individuals are less likely to transmit the virus or get sick. Getting vaccinated and receiving booster shots can save lives and prevent the spread of infection. The goal is to become a dead end for the virus, stopping its transmission. Vaccinated people do not get infected and cannot be used as hosts to spread the virus. However, the initial emergency use authorization did not have sufficient data on the vaccine's effectiveness against transmission. The speed of scientific progress necessitated quick action.

The speaker acknowledges that the vaccine did not completely stop the spread or infection, but clarifies that initially it did for the Wuhan strain and the alpha strain. Early data and literature published in the New England Journal showed that those who were vaccinated and didn't get infected were not transmitting the virus to others. The vaccine had a high efficacy of up to 96% early on and this efficacy did not change over time.

Developing a vaccine is crucial to controlling the pandemic. Normally, it takes about five years to create a new vaccine, including testing for safety and effectiveness. However, efforts are being made to compress this timeline to around 18 months. The RNA platform shows promise in speeding up production. Ensuring a vaccine's effectiveness and safety, especially for older individuals, is challenging. We must avoid compromising safety while increasing efficacy. Decision-making regarding the use of a new vaccine will be based on limited data to expedite progress. Supporting the development of the most promising candidates, building production facilities, and conducting safety testing require a global collaborative effort. Our foundation is heavily involved in funding vaccines, including for developing countries. It's encouraging to see various medications emerging, such as Moderna, CureVac, Stamovi, and Logovac, which require investment.

The speaker acknowledges that the vaccine did not completely stop the spread or infection, but clarifies that initially it did for the Wuhan strain and the alpha strain. Early data and literature published in the New England Journal showed that those who were vaccinated and didn't get infected were not transmitting the virus to others. The vaccine had a high efficacy of up to 96% early on and this efficacy did not change over time.

Locking down entire populations and shutting down the economy were extreme measures taken to combat the pandemic. However, thanks to globalization, vaccines were developed in a record time of 9 months, compared to the usual 5 years. It is crucial to vaccinate globally to prevent the return of the virus in the form of new variants and increased contagion. Failure to do so will have negative consequences for us. Vaccination is not only important for recovery but also for anticipating future challenges.